H. Lundbeck A Logo

H. Lundbeck A

Develops and commercializes innovative therapeutics for brain diseases globally.

HLUN | CO

Overview

Corporate Details

ISIN(s):
DK0061804697 (+5 more)
LEI:
5493006R4KC2OI5D3470
Country:
Denmark
Address:
Ottiliavej 9, 2500 Valby
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

H. Lundbeck A/S is a global pharmaceutical company dedicated exclusively to developing and commercializing innovative treatments for brain diseases. The company's core focus is on neuroscience, engaging in the full value chain of research, development, manufacturing, and sales of therapeutics for psychiatric and neurological disorders. Its portfolio addresses a variety of conditions, including depression, migraine, and rare epilepsies. With a mission to advance brain health, Lundbeck markets its specialized products in numerous countries worldwide, managing operations from initial research to patient delivery.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 14:51
Regulatory Filings
English 96.8 KB
2025-11-14 12:45
M&A Activity
English 25.3 KB
2025-11-14 12:45
Regulatory Filings
English 96.8 KB
2025-11-11 15:22
Regulatory Filings
English 116.4 KB
2025-11-11 15:22
Earnings Release
English 24.6 KB
2025-09-20 08:00
Regulatory Filings
English 146.2 KB
2025-09-20 08:00
Legal Proceedings Report
English 30.0 KB
2025-08-13 18:41
Interim / Quarterly Report
English 1.0 MB
2025-08-13 18:41
Earnings Release
English 32.1 KB
2025-08-13 18:35
Earnings Release
English 24.2 KB
2025-08-13 18:35
Earnings Release
English 129.5 KB
2025-02-21 13:27
Director's Dealing
English 124.1 KB
2025-02-21 13:27
Director's Dealing
English 29.9 KB
2025-02-05 16:40
Director's Dealing
English 134.1 KB
2025-02-05 16:40
Director's Dealing
English 96.6 KB

Automate Your Workflow. Get a real-time feed of all H. Lundbeck A filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for H. Lundbeck A

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for H. Lundbeck A via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CORCEPT THERAPEUTICS INC Logo
Develops and commercializes cortisol-modulating drugs for severe disorders like Cushing's syndrome.
United States of America
CORT
Corline Biomedical AB Logo
Develops heparin-based coatings for medical device biocompatibility and regenerative medicine.
Sweden
CLBIO
CorMedix Inc. Logo
Develops a catheter lock solution to prevent bloodstream infections in hemodialysis patients.
United States of America
CRMD
Corvus Pharmaceuticals, Inc. Logo
Develops novel, targeted therapies for immune diseases and cancer.
United States of America
CRVS
Cosma Spolka Akcyjna Logo
Produces natural hemp supplements and pharmaceutical raw materials for retail & wholesale markets.
Poland
COS
COSMO Pharmaceuticals N.V. Logo
Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.
Netherlands
COPN
Cosmos Health Inc. Logo
A global healthcare firm developing & distributing nutraceuticals, generics, and OTC medications.
United States of America
COSM
Coya Therapeutics, Inc. Logo
Developing Treg-modulating therapies for neurodegenerative and autoimmune diseases.
United States of America
COYA
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Logo
Biotech firm developing cell therapies for regenerative medicine and immunotherapy applications.
United States of America
CELZ
CRESCENT BIOPHARMA, INC. Logo
A biotech company developing bispecific antibody therapies to treat solid tumors.
United States of America
CBIO

Talk to a Data Expert

Have a question? We'll get back to you promptly.